MAIA Biotechnology is developing novel immune-oncology therapies to treat cancer. MAIA’s lead drug candidate, THIO, is an investigational dual mechanism of action drug that is recognised by the protein telomerase that adds telomeres to the ends of DNA. On recognition of THIO, the compound gets incorporated into the telomere structure resulting in rapid cell death. As telomerase is present in more than 85% of human cancers contributing greatly to the proliferation and reproductive immortality of cancer cells, MAIA is testing THIO in many cancer types. Currently, THIO is being tested in clinical trials for non-small cell lung cancer.

MAIA Biotechnology

MAIA Biotechnology Announces $2.44 Million Private Placement - StockTitan

MAIA Biotech Secures FDA Rare Pediatric Disease Status for Novel Brain Cancer Drug, Eyes $100M Voucher - StockTitan

MAIA Biotechnology nears end of Phase 2 cancer trial - Investing.com


              THIO Plus Cemiplimab Displays Efficacy in Checkpoint Inhibitor–Resistant NSCLC
            

MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings

MAIA Biotechnology has announced the expansion of its clinical supply agreement with Regeneron for the Phase 2 clinical trial of THIO in combination with cemiplimab (Libtayo®) for advanced #NSCLC patients receiving third-line treatment. In keeping with our clinical strategy for THIO, we look forward to continuing our collaboration with Regeneron to evaluate THIO’s anti-tumor activity when followed by PD-(L)1 inhibition. 

In case you missed it, read the press release here: https://bit.ly/3VlyUWt #Biotech #Immunotherapy

RSS News Feed

MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders - StockTitan

View All News


                        
                            Dec 16, 2024 • 8:37am EST
                            MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas
                            View Press Release
                        
                    

Stan Smith Acquires 25,000 Shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Stock - MarketBeat

 MAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung Cancer 

5 Successful Phase III Oncology Trials in Q1 - BioSpace

 MAIA Biotechnology looks to raise $1.33M through a private placement 

Bears are Losing Control Over MAIA Biotechnology, Inc. (MAIA), Here's Why It's a 'Buy' Now - Yahoo Finance

MAIA’s lung cancer therapy offers complete disease control in trial - Clinical Trials Arena

 MAIA Biotechnology Announces $1.00 Million Private Placement 


                        
                            Dec 3, 2024 • 8:17am EST
                            MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer
                            View Press Release
                        
                    

MAIA Biotechnology Announces $2.44 Million Private Placement - Business Wire

MAIA Director Backs Cancer Drug Developer with $225,900 Stock Purchase, Shows Insider Confidence - StockTitan

 MAIA Biotechnology provides update on THIO-101 trial 


              MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas
            

 MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement 

MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board - Yahoo Finance

 MAIA Biotechnology granted FDA rare pediatric disease designation for THIO 

 MAIA Biotechnology directors buy shares amid development push 

 MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings 

MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement - Business Wire

 MAIA Biotechnology reports promising Phase 2 trial results By Investing.com 

 MAIA Biotechnology Announces $1.33 Million Private Placement 

 MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero 

MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients - Benzinga

MAIA Biotechnology: Significantly Undervalued With Novel Mechanism & Impressive Early Data - Seeking Alpha

MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer - Yahoo Finance

Oncology company MAIA advances on news of private placement - Kursiv Media

Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer - The Globe and Mail

MAIA Biotechnology Directors Show Strong Confidence with $573K Personal Investment in Private Placement - StockTitan

MAIA Biotechnology, Regeneron expand clinical supply agreement - TipRanks

 MAIA Biotechnology Announces $2.44 Million Private Placement 

MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement - Yahoo Finance

MAIA Biotechnology Secures $950K Private Placement to Advance THIO Clinical Trials - StockTitan

MAIA Biotechnology - The Pharma Letter

Messi has sales and this stock flying ⚽ - RagingBull

MAIA soars after its cancer drug receives FDA ‘rare pediatric disease’ designation - Kursiv Media

 MAIA Biotechnology announces $950,000 private placement (NYSE:MAIA) 

MAIA Biotechnology Reports Full Year 2022 Financial Results and Provides Corporate Update - Marketscreener.com

MAIA - MAIA Biotechnology, Inc. Latest Stock News & Market Updates - StockTitan

Maia Biotechnology posts first quarterly earnings report after going public - The Business Journals

Big Moves at MAIA Biotechnology! Insider Buying and Market Insights - Clinique Bio

MAIA Biotechnology';s Telomere Targeting Functionality is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy - StockTitan

 MAIA Biotechnology prices $2.44M private placement (NYSE:MAIA) 

MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting - Business Wire

Maia Biotechnology director Stan Smith acquires $46,800 in stock - Investing.com

 MAIA Biotechnology Shares Rise After FDA's Telomerase Inhibitor Approval Shows Viability of Such Therapies 


              Telomere-targeting agent granted Rare Pediatric Disease designation - Drug Discovery World (DDW)
            

MAIA Biotech releases Phase II results for THIO - The Pharma Letter

 MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer 

MAIA Biotechnology reports positive data from NSCLC therapy trial - Clinical Trials Arena

MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings - Business Wire


                        
                            Dec 9, 2024 • 6:00pm EST
                            MAIA Biotechnology Announces Private Placement of Approximately $950,000
                            View Press Release
                        
                    

What is a checkpoint inhibitor? In our new CEO spotlight series, Vlad Vitoc, MD, MBA, dives into this drug that helps the immune system attack cancer cells. 

Find out by watching the video clip below and stay tuned for more as Vlad brings you firsthand insights from the #biotech world. #Oncology #OncNews #Immunotherapy

MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance

 MAIA Biotechnology to sell 507,364 shares at $1.872 in private placement 

THIO Shows Lower Toxicity Than Standard Treatments in NSCLC Study - Targeted Oncology

 MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients 

MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent - Yahoo Finance

MAIA Biotech Expands Cancer Trial with Regeneron, Reports Promising NSCLC Results - StockTitan

Investing Insights: MAIA Biotechnology’s Promising Moves - Clinique Bio

Recent Run-Up Provides MAIA Biotechnology With Breathing Room (NYSE:MAIA) - Seeking Alpha

 MAIA Biotechnology secures funding through private placement By Investing.com 

 Director Ngar Louie Acquires 170,940 Shares of MAIA Biotechnology Inc (MAIA) 

MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer - Yahoo Finance

Maia Biotechnology director Smith acquires shares worth $299,408 By Investing.com - Investing.com Australia

 MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement 

MAIA Biotechnology (NYSE: MAIA) Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer. Read the press release here: https://bit.ly/3VlyUWt #NSCLC #Biotech

As we approach the close of a remarkable year, we are proud to share the key accomplishments in 2024 and the exciting path ahead for MAIA Biotechnology. In 2024, we:

• Expanded our impact, visibility and value proposition as a company offering a new science for cancer therapy. 
• Achieved exceptional and unmatched measures of efficacy in our THIO-101 Phase 2 trial in NSCLC. 

In our latest data released:

• 19 patients had survival follow-up over 12 months
• DCR was 85% vs 25-35% for chemotherapy
• We remain on track to achieve our overall survival goals for THIO-101.
• Advanced THIO through the clinic with multiple clinical studies planned for 2025.
• The next stage of our NSCLC trials will further assess THIO’s efficacy in third line NSCLC patients.

CEO Vlad Vitoc, MD, MBA comments, “We are prepared to kick off 2025 with exciting milestones in reach. Our accomplishments mark significant strides toward our mission to redefine cancer care, and our confidence continues to grow for our novel science and clinical pathways for our immuno-oncology therapies.”

Wishing everyone a joyful holiday season and a prosperous New Year!

MAIA Biotech's NSCLC Treatment Shows 83% Survival Boost Over Standard Care in Trial - StockTitan

MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - Yahoo Finance

 MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement 

 MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory ... 

Maia Biotechnology director Luput acquires shares worth $55,553 - Investing.com

MAIA Biotechnology, Inc. Announces Pricing of Public Offering - Business Wire

MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas - Business Wire

 MAIA Biotechnology Shares Hit 52-Week High After Director Stock Purchase 

This week, MAIA announced that the FDA has designated THIO for the treatment of pediatric-type diffuse high-grade gliomas (#PDHGG) as a drug for a “rare pediatric disease.” 

MAIA’s Vice President and Head of Regulatory and Quality K. Robinson Lewis comments, “Rare pediatric disease designation also offers a highly valuable incentive for MAIA. Upon FDA approval of a future new drug application in PDHGG, MAIA would be eligible to receive a priority review voucher that can be redeemed or sold as an asset at a very high valuation.”

Previous research showcased THIO’s potency as a treatment for a PDHGG subtype known as diffuse intrinsic pontine glioma (DIPG).

In case you missed the news, dive into the press release here: https://bit.ly/3ZHubzQ #Biotech

"We look forward to continuing our collaboration with Regeneron to evaluate THIO’s anti-tumor activity when followed by PD-(L)1 inhibition," said MAIA’s CEO Vlad Vitoc, MD, MBA. "So far, THIO-101 has demonstrated favorable disease control, progression free survival, overall response rates, and we remain on track to achieve our overall survival goals.” 

Read the press release here:  https://bit.ly/3D0K64K 

#Biotech #Pharmaceutical #Oncology #ClinicalResearch

MAIA Biotechnology announces $950,000 private placement - MSN

 MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer 

MAIA Biotechnology Announces Pricing of Initial Public Offering - Business Wire

MAIA Biotechnology to sell 507,364 shares at $1.872 in private placement - TipRanks

CEO Spotlight on granted FDA rare pediatric disease designation for THIO as a treatment for high-grade gliomas:

“THIO is a versatile anti-cancer agent that has demonstrated positive results in multiple difficult to treat cancer types, including pediatric high-grade glioma, which is among the most treatment-resistant cancers in children. THIO is shown to activate the immune system while evading tumor immunosuppression, a novel therapeutic approach for this devastating childhood disease.

We are proud to receive the FDA’s Rare Pediatric Disease designation for THIO, which significantly bolsters our plans for continuing research in the PDHGG indication,” comments Vlad Vitoc, MD, MBA.

Read more in the press release: https://bit.ly/3ZHubzQ

 MAIA Biotechnology Announces Private Placement of Approximately $950,000 

 MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting 

Maia Biotechnology director Ramiro Guerrero buys $99,998 in stock - Investing.com

THIO Followed by Cemiplimab Leads to Potential OS Benefit in Pretreated Advanced NSCLC - OncLive

 MAIA Biotechnology (MAIA) Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer 

 MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas 

 MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement 

 MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 ... 

MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - Yahoo Finance

MAIA Biotechnology

Business:

Drug notes:

About: